Clinical Trials Logo

NSCLC, Stage III clinical trials

View clinical trials related to NSCLC, Stage III.

Filter by:

NCT ID: NCT04585490 Recruiting - Clinical trials for Non Small Cell Lung Cancer

Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC

Start date: August 25, 2021
Phase: Phase 3
Study type: Interventional

The purpose of this study is to test whether or not number of circulating cancer cells detected in the blood can be decreased the by combining the standard treatment (durvalumab) with Tremelimumab and additional chemotherapy

NCT ID: NCT04351256 Recruiting - NSCLC, Stage III Clinical Trials

Thoracic Radiotherapy Plus Durvalumab in Elderly and/or Frail NSCLC Stage III Patients Unfit for Chemotherapy

TRADE-hypo
Start date: May 20, 2020
Phase: Phase 2
Study type: Interventional

This is a randomized, open-label, multicenter, phase II trial investigating the combination of thoracic radiotherapy plus Durvalumab in patients with locally advanced, unresectable NSCLC (stage III) that are unfit for chemotherapy (e.g. due to age and/or frailty).

NCT ID: NCT04202809 Recruiting - NSCLC, Stage III Clinical Trials

Phase-II Trial of Induction Chemotherapy and Chemoradiotherapy Plus/Minus Durvalumab and Consolidation Immunotherapy in Patients With Resectable Stage III NSCLC.

ESPADURVA
Start date: January 13, 2020
Phase: Phase 2
Study type: Interventional

To compare a complex induction multimodality protocol (ESPATUE) + concurrent immunotherapy with PD-L1 antibody Durvalumab given every three weeks to the same induction multimodality protocol without Durvalumab immunotherapy induction followed by definitive local treatment (surgery for those considered resectable or chemoradiation boost for those not considered to be R0-resectable) followed by consolidation Durvalumab treatment in both arms.

NCT ID: NCT03454685 Recruiting - Healthy Subjects Clinical Trials

The Role of Microbiota on the Development of Lung Cancer

Start date: January 30, 2018
Phase:
Study type: Observational

Relationship between human microbiota and epidemiology of lung cancer